-

Favorable Clinical Data for Applaud Medical’s Novel Technology for Treating Urinary Stones Presented During the 2024 AUA Annual Meeting

SAN FRANCISCO--(BUSINESS WIRE)--Applaud Medical, an emerging leader in the treatment of urinary stones, today announced positive results from a prospective, multicenter study of the company’s BRIO Enhanced Lithotripsy System (ELS) for the treatment of obstructive ureteral stones. The results were presented as a podium presentation during the American Urological Association's (AUA) 2024 Annual Meeting held in San Antonio, Texas. The study combined Applaud Medical’s proprietary acoustically enhanced microbubbles with a low-pressure ultrasound system to treat ureteral stones. When assessed by CT-scan 30 days following the procedure, 72% of the patients who underwent the treatment had no urinary stone fragment greater than 3 millimeters following a single treatment.

“Our study provided initial clinical data demonstrating the safety and efficacy of acoustic cavitation lithotripsy for the treatment ureteral stone disease,” stated Scott Wiener, MD, Assistant Professor of Urology and Director of the Kidney Stone Program at SUNY Upstate Medical University in Syracuse, New York. “The single treatment stone free rate we observed in this study exceeded that previously reported for both the spontaneous passage of ureteral stones (adjusted for size and location), as well as shockwave lithotripsy of ureteral stones. These data provide the foundation for further clinical research using this exciting new approach to urinary stone management.”

“The currently available options for treatment of urinary stones often require patients to wait extended periods of time prior to obtaining surgical treatment while enduring both the pain and disruption to their lives,” said Paul Molloy, CEO of Applaud Medical. “We are developing the BRIO System to change the standard of care, combining our patented calcium-seeking microbubbles with our proprietary low-pressure ultrasound console and ultrasound beam sensing catheter to treat patients suffering with urinary stone disease. Our solution aims to eliminate ureteral stones quickly, affordably, and without general anesthesia or fluoroscopy, bringing it to a physician’s office and other non-hospital settings.”

About Applaud Medical

Applaud Medical is a privately held company which aims to improve treatment methods, patient experiences and medical costs for all patients experiencing the effects of urinary stones. The company’s initial technology is designed to offer patients and healthcare professionals a fast, minimally invasive solution for treating urinary stone disease in various clinical or outpatient settings, eliminating the routine need for anesthesia or X-ray imaging.

For more information, visit www.applaudmedical.com/

Contacts

Paul Molloy
Chief Executive Officer
Applaud Medical, Inc.
Email: paul.molloy@applaudmedical.com
Tel: (415) 887-2037

Applaud Medical


Release Summary
Favorable Clinical Data for Applaud Medical’s Novel Technology for Treating Urinary Stones Presented During the 2024 AUA Annual Meeting
Release Versions

Contacts

Paul Molloy
Chief Executive Officer
Applaud Medical, Inc.
Email: paul.molloy@applaudmedical.com
Tel: (415) 887-2037

Social Media Profiles
More News From Applaud Medical

Avvio Medical’s Microbubble Technology Reduces Complications and Shows Promise for Enhancing Laser Lithotripsy: AEROLITH Trial Results Published in The Journal of Urology

SAN FRANCISCO--(BUSINESS WIRE)--Avvio Medical Inc. today announced the publication of its AEROLITH randomized clinical trial in The Journal of Urology. Study highlights were presented at the 2025 American Urological Association (AUA) Annual Meeting in Las Vegas, Nevada. The AEROLITH study evaluated the safety and effectiveness of Acoustic Enhancer Microbubble Cavitation (AEMC) when used with ureteroscopic laser lithotripsy (URS-LL) to treat kidney and ureteral stones. Study highlights include:...

Avvio Medical Proudly Announces ISO 13485 Certification, Marking a Major Milestone in Global MedTech Readiness

SAN FRANCISCO--(BUSINESS WIRE)--Avvio Medical, Inc., a clinical-stage medical device company focused on transforming the treatment of kidney stone disease, is proud to announce that it has successfully achieved ISO 13485:2016 certification following its initial audit conducted by BSI (British Standards Institution). This globally recognized certification demonstrates Avvio’s compliance with international standards for medical device quality management systems and reflects the company’s unwaveri...

Avvio Medical Announces First Patients Treated with Groundbreaking Kidney Stone Therapy

SAN FRANCISCO--(BUSINESS WIRE)--Avvio Medical, Inc. (formerly Applaud Medical, Inc.) today announced the successful treatment of the first patients using its investigational Enhanced Lithotripsy System (ELS), a pioneering advancement in kidney stone therapy. This milestone follows the company’s recent approval of its Investigational Device Exemption (IDE) by the U.S. Food and Drug Administration (FDA), marking the official launch of its clinical trial. “Our team has developed a world-class solu...
Back to Newsroom